Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
Patients who present to clinic or in the outpatient setting with worsening heart failure
represent a unique opportunity for novel approaches to decongestion (removing fluid) that may
more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization.
In these patients with less severe congestion (fluid overload), combining the vasopressin
antagonist tolvaptan with loop diuretics (or fluid pills like
furosemide/bumetanide/torsemide) may represent a more effective strategy for decongestion. In
addition, looking at patients' copeptin levels may help identify those who are more likely to
respond to tolvaptan.